On January 17, BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical STAA executed a significant insider buy, as disclosed in the latest SEC filing.

Stifel Nicolaus analyst Thomas Stephan has maintained their bullish stance on STAA stock, giving a Buy rating on January 7.Stay Ahead of the ...

On January 17, BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical (NASDAQ:STAA) executed a significant insider buy, as disclosed in the latest SEC filing. What Happened: In a recent Form 4 filing ...

LAKE FOREST, Calif., January 13, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical (NASDAQ:STAA), a company known for its ophthalmic goods. Neal C. Bradsher, President of Broadwood Capital ...

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical (NASDAQ:STAA), a company known for its ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Staar Surgical Co. (Symbol: STAA) entered into oversold territory, hitting an RSI reading ...

STAAR Surgical has a one year low of $22.40 and a one year high of $52.68. The company has a fifty day moving average of $26.43 and a 200-day moving average of $32.94.

STAAR Surgical (NASDAQ:STAA – Get Free Report)‘s stock had its “hold” rating reiterated by investment analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.